Hepatic ischemia-reperfusion injury (IRI) represents a major risk factor of early graft dysfunction and acute/chronic rejection as well as a key obstacle to expanding the donor pool in orthotopic liver transplantation (OLT). Although glucocorticoid receptor (GR) signaling may enhance cytoprotective programs, clinical use of glucocorticoid is limited because of adverse effects, whereas clinical relevance of GR-facilitated cytoprotection in OLT remains unknown. We aimed to evaluate the significance of hepatic GR in clinical OLT and verify the impact of recombinant human relaxin (rhRLX), which may function as a GR agonist in a tissue/disease-specific manner. Fifty-one OLT patients were recruited under an institutional research board (IRB) protocol. Liver biopsies were collected after cold storage (presurgery) and 2 hours postreperfusion (before abdominal closure), followed by western blotting-assisted hepatic analyses. Forty-three percent of OLTs failed to increase GR perioperatively under surgical stress. Post-/pre-GR ratios at postoperative day 1 correlated negatively with serum aspartate aminotransferase (AST)/cleaved caspase-3 and positively with B-cell lymphoma-extra large (Bcl-xL)/B-cell lymphoma 2 (Bcl-2) levels. In a murine OLT model with extended (18-hour) cold storage, treatment with rhRLX ameliorated ischemia-reperfusion (IR) damage and improved survival while up-regulating hepatocyte GR and Bcl-xL/Bcl-2 expression in OLT. rhRLX-induced GR suppressed hepatocyte high-mobility group box 1 (HMGB1) translocation/release, accompanied by decreased Toll-like receptor 4 (TLR4)/receptor for advanced glycation end products (RAGE), suppressed interleukin 1 beta (IL1β), chemokine (C-C motif) ligand 2 (CCL2), C-X-C motif chemokine (CXCL)10, tumor necrosis factor alpha (TNFα), CXCL1, and CXCL2 levels, and attenuated neutrophil/macrophage accumulation in OLT. Inhibition of GR in hepatocyte culture and in OLT diminished rhRLX-mediated cytoprotection. CONCLUSION: This translational study underscores the role of rhRLX-GR signaling as a regulator of hepatocellular protection against IR stress in OLT. In the context of a recent phase III clinical trial demonstrating positive outcomes of rhRLX in patients with acute heart failure, studies on rhRLX for the management of IRI in OLT recipients are warranted. (Hepatology 2018;68:258-273).
Hepatic ischemia-reperfusion injury (IRI) represents a major risk factor of early graft dysfunction and acute/chronic rejection as well as a key obstacle to expanding the donor pool in orthotopic liver transplantation (OLT). Although glucocorticoid receptor (GR) signaling may enhance cytoprotective programs, clinical use of glucocorticoid is limited because of adverse effects, whereas clinical relevance of GR-facilitated cytoprotection in OLT remains unknown. We aimed to evaluate the significance of hepatic GR in clinical OLT and verify the impact of recombinant human relaxin (rhRLX), which may function as a GR agonist in a tissue/disease-specific manner. Fifty-one OLT patients were recruited under an institutional research board (IRB) protocol. Liver biopsies were collected after cold storage (presurgery) and 2 hours postreperfusion (before abdominal closure), followed by western blotting-assisted hepatic analyses. Forty-three percent of OLTs failed to increase GR perioperatively under surgical stress. Post-/pre-GR ratios at postoperative day 1 correlated negatively with serum aspartate aminotransferase (AST)/cleaved caspase-3 and positively with B-cell lymphoma-extra large (Bcl-xL)/B-cell lymphoma 2 (Bcl-2) levels. In a murine OLT model with extended (18-hour) cold storage, treatment with rhRLX ameliorated ischemia-reperfusion (IR) damage and improved survival while up-regulating hepatocyte GR and Bcl-xL/Bcl-2 expression in OLT. rhRLX-induced GR suppressed hepatocyte high-mobility group box 1 (HMGB1) translocation/release, accompanied by decreased Toll-like receptor 4 (TLR4)/receptor for advanced glycation end products (RAGE), suppressed interleukin 1 beta (IL1β), chemokine (C-C motif) ligand 2 (CCL2), C-X-C motif chemokine (CXCL)10, tumor necrosis factor alpha (TNFα), CXCL1, and CXCL2 levels, and attenuated neutrophil/macrophage accumulation in OLT. Inhibition of GR in hepatocyte culture and in OLT diminished rhRLX-mediated cytoprotection. CONCLUSION: This translational study underscores the role of rhRLX-GR signaling as a regulator of hepatocellular protection against IR stress in OLT. In the context of a recent phase III clinical trial demonstrating positive outcomes of rhRLX in patients with acute heart failure, studies on rhRLX for the management of IRI in OLT recipients are warranted. (Hepatology 2018;68:258-273).
Authors: Edna D Lekgabe; Helen Kiriazis; Chongxin Zhao; Qi Xu; Xiao Lei Moore; Yidan Su; Ross A D Bathgate; Xiao-Jun Du; Chrishan S Samuel Journal: Hypertension Date: 2005-06-20 Impact factor: 10.190
Authors: G Bilbao; J L Contreras; D E Eckhoff; G Mikheeva; V Krasnykh; J T Douglas; F T Thomas; J M Thomas; D T Curiel Journal: Ann Surg Date: 1999-08 Impact factor: 12.969
Authors: John R Teerlink; Gad Cotter; Beth A Davison; G Michael Felker; Gerasimos Filippatos; Barry H Greenberg; Piotr Ponikowski; Elaine Unemori; Adriaan A Voors; Kirkwood F Adams; Maria I Dorobantu; Liliana R Grinfeld; Guillaume Jondeau; Alon Marmor; Josep Masip; Peter S Pang; Karl Werdan; Sam L Teichman; Angelo Trapani; Christopher A Bush; Rajnish Saini; Christoph Schumacher; Thomas M Severin; Marco Metra Journal: Lancet Date: 2012-11-07 Impact factor: 79.321
Authors: Pascal O Berberat; Helmut Friess; Bruno Schmied; Michael Kremer; Stefanie Gragert; Christa Flechtenmacher; Peter Schemmer; Jan Schmidt; Thomas Kraus; Waldemar Uhl; Stefan Meuer; Markus W Büchler; Thomas Giese Journal: Transplantation Date: 2006-09-15 Impact factor: 4.939
Authors: Shoichi Kageyama; Hirofumi Hirao; Kojiro Nakamura; Bibo Ke; Min Zhang; Takahiro Ito; Antony Aziz; Damla Oncel; Fady M Kaldas; Ronald W Busuttil; Rebecca A Sosa; Elaine F Reed; Jesus A Araujo; Jerzy W Kupiec-Weglinski Journal: Am J Transplant Date: 2018-08-24 Impact factor: 8.086
Authors: Kojiro Nakamura; Shoichi Kageyama; Fady M Kaldas; Hirofumi Hirao; Takahiro Ito; Kentaro Kadono; Kenneth J Dery; Hidenobu Kojima; David W Gjertson; Rebecca A Sosa; Maciej Kujawski; Ronald W Busuttil; Elaine F Reed; Jerzy W Kupiec-Weglinski Journal: J Clin Invest Date: 2020-05-01 Impact factor: 14.808
Authors: Yaochun Wang; Yang Yang; Meng Wang; Shuhong Wang; Jong-Min Jeong; Long Xu; Yankai Wen; Christoph Emontzpohl; Constance Lynn Atkins; Kevin Duong; Nicolas F Moreno; Xiaoyi Yuan; David R Hall; Wasim Dar; Dechun Feng; Bin Gao; Yong Xu; Zoltan Czigany; Sean P Colgan; J Steve Bynon; Shizuo Akira; Jared M Brown; Holger K Eltzschig; Elizabeth A Jacobsen; Cynthia Ju Journal: Sci Transl Med Date: 2021-02-03 Impact factor: 17.956
Authors: Cynthia Ju; Meng Wang; Eunyoung Tak; Boyun Kim; Christoph Emontzpohl; Yang Yang; Xiaoyi Yuan; Huban Kutay; Yafen Liang; David R Hall; Wasim A Dar; J Steve Bynon; Peter Carmeliet; Kalpana Ghoshal; Holger K Eltzschig Journal: J Clin Invest Date: 2021-04-01 Impact factor: 14.808
Authors: Takahiro Ito; Kojiro Nakamura; Shoichi Kageyama; Islam M Korayem; Hirofumi Hirao; Kentaro Kadono; Justine Aziz; Stephanie Younan; Joseph DiNorcia; Vatche G Agopian; Hasan Yersiz; Douglas G Farmer; Ronald W Busuttil; Jerzy W Kupiec-Weglinski; Fady M Kaldas Journal: Liver Transpl Date: 2019-11-04 Impact factor: 5.799